These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26161927)

  • 21. Impact of 3'UTR variation patterns of the KRAS gene on the aggressiveness of pancreatobiliary tumors with the KRAS G13D mutation in a Turkish population.
    Egeli U; Ak S; Cecener G; Tunca B; Tezcan G; Sevinc ED; Kaya E; Dundar HZ; Sarkut P; Ozen Y; Balcin O; Evrensel T; Yerci O; Ugras N
    Pancreatology; 2016; 16(4):677-86. PubMed ID: 27256640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.
    Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
    JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
    Marks JL; Broderick S; Zhou Q; Chitale D; Li AR; Zakowski MF; Kris MG; Rusch VW; Azzoli CG; Seshan VE; Ladanyi M; Pao W
    J Thorac Oncol; 2008 Feb; 3(2):111-6. PubMed ID: 18303429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
    Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
    Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.
    Porta M; Pumarega J; Amaral AFS; Genkinger JM; Camargo J; Mucci L; Alguacil J; Gasull M; Zhang X; Morales E; Iglesias M; Ogino S; Engel LS;
    Environ Res; 2020 Nov; 190():109781. PubMed ID: 32791343
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Shiroma N; Arihiro K; Oda M; Orita M
    J Clin Pathol; 2018 Oct; 71(10):865-873. PubMed ID: 29695486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.
    Takai E; Totoki Y; Nakamura H; Morizane C; Nara S; Hama N; Suzuki M; Furukawa E; Kato M; Hayashi H; Kohno T; Ueno H; Shimada K; Okusaka T; Nakagama H; Shibata T; Yachida S
    Sci Rep; 2015 Dec; 5():18425. PubMed ID: 26669280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
    Wright GP; Chesla DW; Chung MH
    Am J Surg; 2016 Mar; 211(3):506-11. PubMed ID: 26754455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance.
    Miglio U; Oldani A; Mezzapelle R; Veggiani C; Paganotti A; Garavoglia M; Boldorini R
    Pathol Res Pract; 2014 May; 210(5):307-11. PubMed ID: 24629489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.
    Ostrow SL; Simon E; Prinz E; Bick T; Shentzer T; Nagawkar SS; Sabo E; Ben-Izhak O; Hershberg R; Hershkovitz D
    Sci Rep; 2016 Feb; 6():21927. PubMed ID: 26902163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenesis and the clinical significance of K-ras in pancreatic adenocarcinoma.
    Huang C; Wang WM; Gong JP; Yang K
    Asian Pac J Cancer Prev; 2013; 14(5):2699-701. PubMed ID: 23803017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma.
    Wang C; Shi M; Zhang L; Ji J; Xie R; Wu C; Guo X; Yang Y; Zhou W; Peng C; Zhang H; Yuan F; Zhang J
    Cancer Immunol Immunother; 2022 Feb; 71(2):491-504. PubMed ID: 34255132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma.
    Huang C; Huang R; Chang W; Jiang T; Huang K; Cao J; Sun X; Qiu Z
    Neoplasma; 2012; 59(1):52-61. PubMed ID: 22082308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
    Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
    Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
    Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
    Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes.
    Zou S; Zhang L; Jiang C; Li F; Yang Y; Deng X; Zhang J; Chen H; Jiang L; Cheng X; Deng L; Lin L; Shen B; Wen C; Zhan Q
    Cancer Lett; 2024 Sep; 599():217134. PubMed ID: 39094824
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA
    JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.
    Ma Z; Li Z; Ma Z; Zhou Z; Zhuang H; Liu C; Huang B; Zou Y; Zheng Z; Yang L; Gong Y; Huang S; Zhou Q; Zhang C; Hou B
    Biomed Res Int; 2021; 2021():9949272. PubMed ID: 34660806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.